BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32643174)

  • 1. Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.
    Olszewska B; Żawrocki A; Lakomy J; Karczewska J; Gleń J; Zabłotna M; Malek M; Jankau J; Lange M; Biernat W; Nowicki RJ; Sokołowska-Wojdyło M
    Int J Dermatol; 2020 Sep; 59(9):1106-1112. PubMed ID: 32643174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
    Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
    Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
    Luna DE; Shinohara MM
    Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
    J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
    Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
    Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
    Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM; Cerroni L
    Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.
    Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2377-2387. PubMed ID: 34331819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
    Parker SR; Bethaney JV
    G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
    Shareef MM; Elgarhy LH; Wasfy Rel-S
    Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
    Quadri I; Reneau JC; Hanel W; Chung CG
    Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Leroy S; Dubois S; Tenaud I; Chebassier N; Godard A; Jacques Y; Dréno B
    Br J Dermatol; 2001 May; 144(5):1016-23. PubMed ID: 11359391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
    Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.